Navigation Links
Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits,Potential for New Approach to the Treatment and Prevention of,Breast Cancer

in the development of pharmaceutical products that address conditions of the male and female reproductive systems. Proellex, the Company's lead compound, a PRM (progesterone receptor modulator) has recently completed a successful U.S. three-month Phase 2 clinical trial for the treatment of uterine fibroids, a condition that affects numerous women of childbearing age in the United States and results in a significant number of hysterectomies each year. Proellex has recently completed a six-month European Phase 1/2 study for the treatment of endometriosis, a condition that affects approximately 5.5 million women in the United States and Canada. Androxal(TM), the Company's other program in late clinical development, is designed to restore normal testosterone production by the testes and has recently completed a six-month U.S. non-pivotal Phase 3 clinical trial for the treatment of testosterone deficiency in men due to secondary hypogonadism. According to industry sources, approximately 13 million men in the United States experience testosterone deficiency. The Company is planning meetings with the FDA for all three programs to lay out the remaining clinical program pathway required before a New Drug Application may be submitted for each product candidate.

For more information, please visit the Company's website at http://www.reprosrx.com.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have success in the clinical development of its technologies, the timing of enrollment in such clinical studies and the accuracy of such studies, Repros' ability to raise additional capital on acceptable terms or at all, and such other risks which are identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and Repros' Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, as they may be updated by the Comp
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medicures MEND-CABG Trial Results Published in Peer Reviewed Journal
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
5. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
6. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
9. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... Dec. 14, 2010 Samplify Systems, Inc., a ... the ultrasound market, is pleased to announce that ... has won Electronic Design Magazine,s Best ... category.  Details of Samplify,s AutoFocus™ beamforming technology currently ...
... 14, 2010 Pacira Pharmaceuticals, Inc. ... the New Drug Application (NDA) for EXPAREL™, a long-acting ... filing by the U.S. Food and Drug Administration (FDA). ... the initial indication of postsurgical analgesia by local administration. ...
Cached Medicine Technology:Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2
(Date:8/31/2015)... ... August 31, 2015 , ... GenHart Software, LLC, a rising player in ... small businesses operate as efficiently and cost effectively as possible, with a belief that ... their first year of operation – and the Charleston business community is taking notice. ...
(Date:8/30/2015)... , ... August 31, 2015 , ... Avid collector Andrew ... the Doors Shrine Auditorium concert posters. This hand colored artwork is one of the ... in Los Angles. Hawley states, "When the doors played the Shrine, the band ...
(Date:8/30/2015)... DE (PRWEB) , ... August 31, 2015 , ... ... exhibitor at the AHCA/NCAL 66th Annual Convention & Expo October 5th & 6th ... and organizations together, the AHCA/NCAL convention brings industry professionals from all over the ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... across platforms and devices, today announced it is a Silver Sponsor of the ... at Sky City Convention Centre in Auckland, NZ. Throughout the event, AvePoint will ...
(Date:8/30/2015)... ... ... Natural Rest contains a unique mixture of vitamins and herbs that are ... to improve mood disorders and anxiety. Like all other Creative Medical Health products, Natural ... regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one of ...
Breaking Medicine News(10 mins):Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2
... woman who comes to a health care centre does increase ... partners, a new study confirms. The study, led by ... at St. Michael,s Hospital, represents a major reversal of thinking ... or intimate partner violence. Until now, the research and ...
... around 2 billion dollars a year on remediation at ... used for groundwater monitoring. Yet according to Rolf Halden, ... information gathered is often of limited value. Under ... Department of Defense, Halden, assistant director at the Institute,s ...
... -- The sooner rehabilitation begins after knee replacement, the ... In the study, published March 7 in the ... than 150 patients who began rehabilitation within 24 hours ... of patients who began rehabilitation 48 to 72 hours ...
... , FRIDAY, March 4 (HealthDay News) -- In what experts ... have for the first time turned human embryonic stem cells ... of brain cell that,s lost to Alzheimer,s disease. The ... cholinergic" (BFC) neurons, is key to the progression of Alzheimer,s. ...
... Walter and Eliza Hall Institute have identified the key ... response. The finding could have wide-ranging repercussions for ... and change how the efficacy of newly developed drugs ... Erika Cretney, Dr Axel Kallies and Dr Stephen Nutt ...
... Sledding is the most common cause of injury among winter ... list of the top five injury-causing winter activities. "More ... States due to sledding. More than 30 percent are head ... specialist at Gottlieb Memorial Hospital in Melrose Park, Ill., part ...
Cached Medicine News:Health News:Universal screening programs can uncover abuse, study finds 2Health News:Monitoring waste in groundwater (without all the waste) 2Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 2Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 3Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 4Health News:Newly identified cell population key to immune response 2
Cold light source single outlet....
... The 4150S is a state ... halogen light source with an ... standard coupler to connect optical ... source distinguishes itself from all ...
The 9300XSP is the brightest light source available. Visualize more clearly, see color more accurately, and work more effectively. Luxtecs xenon lighting delivers bright, white light that is as close...
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Medicine Products: